Action LLY ELI LILLY AND COMPANY
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués Eli Lilly and Company Euronext Paris

Actions

LLY

US5324571083

Temps réel Euronext Paris
Autres places de cotation
 16:05:35 29/10/2019 		Varia. 5j. Varia. 1 janv.
98 EUR -1,01 % Graphique intraday de Eli Lilly and Company -.--% +2,08 %
18/06 Un ETF perte de poids MT
14/06 Musk obtient l'approbation de sa rémunération, mais reste confronté à l'effondrement de l'action Tesla et à sa forte valorisation RE

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Lilly's tirzepatide was superior to placebo for MASH resolution, and more than half of patients achieved improvement in fibrosis at 52 weeks
PR
Lilly announces departure of Anat Ashkenazi, chief financial officer
PR
Eli Lilly and Company - Melissa Seymour to join Lilly as executive vice president of Global Quality
AQ
Silo Pharma's (NASDAQ: SILO) Promising Developments and Key Insights for Traders and Investors
AQ
Eli Lilly and : Asco Lilly Oncology Presentation
PU
AKTIS ONCOLOGY NAMES TYLER BENEDUM, Ph.D., CHIEF TECHNICAL OFFICER
AQ
Lilly, UNICEF expand support to help millions of young people at risk of noncommunicable diseases
PR
NanoViricides (NNVC) Strengthens Drug Development Efforts with Calvert Labs Partnership and Announces Promising RSV Study Results
AQ
Lilly to Participate in Goldman Sachs 45th Annual Global Healthcare Conference
PR
Major manufacturing investment to support API production for tirzepatide
AQ
Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro
AQ
Eli Lilly and : 2015 Global Health Programs Report
PU
Lilly Increases Manufacturing Investment to $9 Billion at Newest Indiana Site to Boost API Production for Tirzepatide and Pipeline Medicines
PR
Keysight Technologies, Nordson fall; Eli Lilly, Lam Research rise, Tuesday, 5/21/2024
AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation
AQ
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
PR
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
PR
Eli Lilly and : Lilly Update on Mounjaro® and Zepbound® (tirzepatide) Compounding Litigation
PU
Eli Lilly and : Lilly Statement on FDA Advisory Committee Meeting on Donanemab for Early Symptomatic Alzheimer’s Disease
PU
Lilly Declares Second-Quarter 2024 Dividend
PR
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action LLY
  4. Action LLY
  5. Actualités Eli Lilly and Company
  6. Communiqués